Sivraj Muralikrishnan, MD, analyzed HARMONi-6 safety findings for ivonescimab in NSCLC, addressing VEGF-related toxicities and global generalizability.
Sivraj Muralikrishnan, MD
Advertisement
Articles by Sivraj Muralikrishnan, MD
Sivraj Muralikrishnan, MD, highlighted top head and neck cancer data from ASCO, including the KEYNOTE-689 trial and the novel mRNA degrader REM-422.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ctDNA MRD Guidance in Bladder Cancer: Pharmacy Specialist on NCCN Updates
2
Sequencing Treatment after EV-Pembro in Urothelial Carcinoma
3
All-Oral AML Regimen Eases Burden on Busy Infusion Centers
4
Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer
5